# Tacrolimus Formulation and Glucose Metabolism After Kidney Transplantation (TAGLUMET Trial)

> **NCT05396898** · PHASE4 · COMPLETED · sponsor: **University Hospital Tuebingen** · enrollment: 44 (actual)

## Conditions studied

- Posttransplant Diabetes Mellitus

## Interventions

- **DRUG:** LCP-tacrolimus
- **DRUG:** twice-daily tacrolimus

## Key facts

- **NCT ID:** NCT05396898
- **Lead sponsor:** University Hospital Tuebingen
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-16
- **Primary completion:** 2023-08-04
- **Final completion:** 2023-12-30
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2024-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05396898

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05396898, "Tacrolimus Formulation and Glucose Metabolism After Kidney Transplantation (TAGLUMET Trial)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05396898. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*